Daniel O'Day (AP Images)

Amid remde­sivir craze Gilead finds time for an­oth­er on­col­o­gy pact — loop­ing in all things NK cells

Gilead’s $4.9 bil­lion buy­out of Forty Sev­en, an­nounced in ear­ly March, land­ed in a dif­fer­ent era be­fore the pan­dem­ic con­sumed bio­phar­ma news. But even amid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.